These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 29661970)

  • 1. Consensus for genes to be included on cancer panel tests offered by UK genetics services: guidelines of the UK Cancer Genetics Group.
    Taylor A; Brady AF; Frayling IM; Hanson H; Tischkowitz M; Turnbull C; Side L;
    J Med Genet; 2018 Jun; 55(6):372-377. PubMed ID: 29661970
    [TBL] [Abstract][Full Text] [Related]  

  • 2. American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility.
    American Society of Clinical Oncology
    J Clin Oncol; 2003 Jun; 21(12):2397-406. PubMed ID: 12692171
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Implementing gene curation for hereditary cancer susceptibility in Australia: achieving consensus on genes with clinical utility.
    Tudini E; Davidson AL; Dressel U; Andrews L; Antill Y; Crook A; Field M; Gattas M; Harris R; Kirk J; Pachter N; Salmon L; Susman R; Townshend S; Trainer AH; Tucker KM; Mitchell G; James PA; Ward RL; Mar Fan H; Poplawski NK; Spurdle AB
    J Med Genet; 2021 Dec; 58(12):853-858. PubMed ID: 33168572
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A descriptive study of UK cancer genetics services: an emerging clinical response to the new genetics.
    Wonderling D; Hopwood P; Cull A; Douglas F; Watson M; Burn J; McPherson K
    Br J Cancer; 2001 Jul; 85(2):166-70. PubMed ID: 11461071
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment.
    Desmond A; Kurian AW; Gabree M; Mills MA; Anderson MJ; Kobayashi Y; Horick N; Yang S; Shannon KM; Tung N; Ford JM; Lincoln SE; Ellisen LW
    JAMA Oncol; 2015 Oct; 1(7):943-51. PubMed ID: 26270727
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Update: variable implementation of the 2018 UKCGG/UKGTN guidelines for breast cancer gene panel tests offered by UK genetics services.
    Wedderburn S; Archer S; Tischkowitz M; Hanson H;
    J Med Genet; 2021 Aug; 58(8):579-580. PubMed ID: 33568439
    [No Abstract]   [Full Text] [Related]  

  • 7. Cancer genetics service provision: a comparison of seven European centres.
    Hopwood P; van Asperen CJ; Borreani G; Bourret P; Decruyenaere M; Dishon S; Eisinger F; Evans DG; Evers-Kiebooms G; Gangeri L; Hagoel L; Legius E; Nippert I; Rennert G; Schlegelberger B; Sevilla C; Sobol H; Tibben A; Welkenhuysen M; Julian-Reynier C
    Community Genet; 2003; 6(4):192-205. PubMed ID: 15331865
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic counselling for hereditary predisposition to ovarian and breast cancer.
    Mackay J; Szecsei CM
    Ann Oncol; 2010 Oct; 21 Suppl 7():vii334-8. PubMed ID: 20943638
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic counselling and testing of susceptibility genes for therapeutic decision-making in breast cancer-an European consensus statement and expert recommendations.
    Singer CF; Balmaña J; Bürki N; Delaloge S; Filieri ME; Gerdes AM; Grindedal EM; Han S; Johansson O; Kaufman B; Krajc M; Loman N; Olah E; Paluch-Shimon S; Plavetic ND; Pohlodek K; Rhiem K; Teixeira M; Evans DG
    Eur J Cancer; 2019 Jan; 106():54-60. PubMed ID: 30471648
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multigene panels in Ashkenazi Jewish patients yield high rates of actionable mutations in multiple non-BRCA cancer-associated genes.
    Frey MK; Sandler G; Sobolev R; Kim SH; Chambers R; Bassett RY; Martineau J; Sapra KJ; Boyd L; Curtin JP; Pothuri B; Blank SV
    Gynecol Oncol; 2017 Jul; 146(1):123-128. PubMed ID: 28495237
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Statement of the American Society of Clinical Oncology: genetic testing for cancer susceptibility, Adopted on February 20, 1996.
    J Clin Oncol; 1996 May; 14(5):1730-6; discussion 1737-40. PubMed ID: 8622094
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Universal Genetic Testing for All Breast Cancer Patients.
    Copur MS
    Oncology (Williston Park); 2019 Aug; 33(8):. PubMed ID: 31469901
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutation prevalence tables for hereditary cancer derived from multigene panel testing.
    Hart SN; Polley EC; Yussuf A; Yadav S; Goldgar DE; Hu C; LaDuca H; Smith LP; Fujimoto J; Li S; Couch FJ; Dolinsky JS
    Hum Mutat; 2020 Aug; 41(8):e1-e6. PubMed ID: 32442341
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improving the referral process for familial breast cancer genetic counselling: findings of three randomised controlled trials of two interventions.
    Wilson BJ; Torrance N; Mollison J; Wordsworth S; Gray JR; Haites NE; Grant A; Campbell MK; Miedyzbrodzka Z; Clarke A; Watson MS; Douglas A
    Health Technol Assess; 2005 Feb; 9(3):iii-iv, 1-126. PubMed ID: 15694064
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic counselling of young women with breast cancer for Li-Fraumeni syndrome: a nationwide survey on the experiences and attitudes of genetics professionals.
    Bakhuizen JJ; Velthuizen ME; Stehouwer S; Bleiker EM; Ausems MG
    Fam Cancer; 2019 Apr; 18(2):231-239. PubMed ID: 30238178
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Key messages for communicating information about BRCA1 and BRCA2 to women with breast or ovarian cancer: Consensus across health professionals and service users.
    Jacobs C; Pichert G; Harris J; Tucker K; Michie S
    Psychooncology; 2017 Nov; 26(11):1818-1824. PubMed ID: 28101941
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An update on genetic risk assessment and prevention: the role of genetic testing panels in breast cancer.
    Piccinin C; Panchal S; Watkins N; Kim RH
    Expert Rev Anticancer Ther; 2019 Sep; 19(9):787-801. PubMed ID: 31469018
    [No Abstract]   [Full Text] [Related]  

  • 18. Analysis of hereditary cancer syndromes by using a panel of genes: novel and multiple pathogenic mutations.
    Tsaousis GN; Papadopoulou E; Apessos A; Agiannitopoulos K; Pepe G; Kampouri S; Diamantopoulos N; Floros T; Iosifidou R; Katopodi O; Koumarianou A; Markopoulos C; Papazisis K; Venizelos V; Xanthakis I; Xepapadakis G; Banu E; Eniu DT; Negru S; Stanculeanu DL; Ungureanu A; Ozmen V; Tansan S; Tekinel M; Yalcin S; Nasioulas G
    BMC Cancer; 2019 Jun; 19(1):535. PubMed ID: 31159747
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Application of Panel-Based Tests for Inherited Risk of Cancer.
    Shah PD; Nathanson KL
    Annu Rev Genomics Hum Genet; 2017 Aug; 18():201-227. PubMed ID: 28504904
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MAGENTA (Making Genetic testing accessible): a prospective randomized controlled trial comparing online genetic education and telephone genetic counseling for hereditary cancer genetic testing.
    Rayes N; Bowen DJ; Coffin T; Nebgen D; Peterson C; Munsell MF; Gavin K; Lechner R; Crase J; Polinsky D; Romero I; Blank SV; Levine DA; Norquist BM; Swisher EM; Lu KH
    BMC Cancer; 2019 Jul; 19(1):648. PubMed ID: 31266460
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.